作者: Mahalapbutr, Panupong ; Okada, Seiji ; Wongkham, Sopit ; Kariya, Ryusho ; Vaeteewoottacharn, Kulthida ; Insawang, Tonkla ; Saisomboon, Saowaluk ; Rungrotmongkol, Thanyada ; Cha'on, Ubon ; Sawanyawisuth, Kanlayanee ; Jitrapakdee, Sarawut

We have previously shown that the overexpression of acetyl-CoA carboxylase 1 (ACC1) was associated with the poor prognosis of cholangiocarcinoma (CCA) patients, and suppression of its expression in CCA cell lines deteriorated cell growth. The present study explored the mechanism by which ACC1 inhibition affects global protein acetylation, using genetic knockdown and pharmacological inhibition with an ACC1 inhibitor ND-646 as models. Both ACC1 knockdown and ACC1-inhibitor-treated cells displayed the hyperacetylation of proteins, accompanied by impaired growth and migration. The immunoprecipitation of hyperacetylated proteins using the anti-acetylated lysine antibody, followed by tandem mass spectrometry, identified three potential verification candidates, namely POTE ankyrin domain family member E, peroxisomal biogenesis factor 1, and heat shock protein 90 beta (HSP90B). HSP90 acetylation was the candidate selected for the verification of protein acetylation. To establish the effects of protein hyperacetylation, treatment with suberoylanilide hydroxamic acid (SAHA), a lysine deacetylase inhibitor, was conducted, and this served as an independent model. Decreased tumor growth but increased acetylated protein levels were observed in ACC1-KD xenograft tumors. Hyperacetylated-alleviated cell growth and migration were consistently observed in the SAHA-treated models. The molecular linkage between protein hyperacetylation and the AKT/GSK3β/Snail pathway was demonstrated. This study highlighted the importance of protein acetylation in CCA progression, suggesting that ACC1 and KDAC are potential targets for CCA treatment.

2023-03-06·The Journal of experimental medicine

Repurposing a tricyclic antidepressant in tumor and metabolism disease treatment through fatty acid uptake inhibition

Article

作者: Song, Yihan ; Zhai, Xuewei ; Chu, Qiaoyun ; Yang, Ronghui ; Liu, Ping ; Li, Binghui ; An, Jing ; Yang, Chuanzhen ; Niu, Jing

Fatty acid uptake is essential for cell physiological function, but detailed mechanisms remain unclear. Here, we generated an acetyl-CoA carboxylases (ACC1/2) double-knockout cell line, which lacked fatty acid biosynthesis and survived on serum fatty acids and was used to screen for fatty acid uptake inhibitors. We identified a Food and Drug Administration–approved tricyclic antidepressant, nortriptyline, that potently blocked fatty acid uptake both in vitro and in vivo. We also characterized underlying mechanisms whereby nortriptyline provoked lysosomes to release protons and induce cell acidification to suppress macropinocytosis, which accounted for fatty acid endocytosis. Furthermore, nortriptyline alone or in combination with ND-646, a selective ACC1/2 inhibitor, significantly repressed tumor growth, lipogenesis, and hepatic steatosis in mice. Therefore, we show that cells actively take up fatty acids through macropinocytosis, and we provide a potential strategy suppressing tumor growth, lipogenesis, and hepatic steatosis through controlling the cellular level of fatty acids.

2022-05-01·FASEB JOURNAL

Zebrafish model of in utero glucose exposure alters developmental programming that leads to life‐long metabolic consequences

Article

作者: Cox, Carol ; Speed, Joshua ; Gibert, Yann ; Konadu, Bridget D.

Background and Aim:

One in ten pregnancies in the US, suffers from Gestational Diabetes Mellitus (GDM). Offspring born to mothers who have GDM have a higher risk of developing Obesity, Type 2 diabetes and Non‐alcoholic fatty liver disease later in life. Although in utero glucose exposure provides evidence for developmental programming leading to metabolic disorders in adults, the molecular mechanisms are still unclear. We aim to understand the mechanisms implicated in developmental programming and their associated adult outcomes in a well‐established zebrafish model of fetal hyperglycemia that mimics the metabolic disorders in human GDM.

Methods:

We developed a zebrafish model of fetal hyperglycemia by exposing embryos to high glucose (4.5% w/v) during the last day of embryogenesis from 96 to 120 hours post fertilization. Glucose level was detected in embryos and larvae homogenates and in adult serum by glucometer. Body composition was determined in adults by EchoMRI, gene expression of glycolytic, lipogenic (Acetyl‐CoA Carboxylase (acca) and mitochondria biogenesis (Peroxisome proliferator‐activated receptor‐gamma coactivator [PGC‐1α/β) markers were quantified by RT‐qPCR and acca by western blot. Lipid accumulation was detected by Oil‐Red‐O staining (ORO) and quantified by spectrophotometry. Triglyceride and cholesterol levels (ELISA), adiposity (Nile red staining) and mitochondrion number (mitotracker staining) were also evaluated. We also assessed if co‐administration of metformin or ND646 (known inhibitors of acca) with glucose can attenuate fetal hyperglycemia‐mediated metabolic outcomes.

Results:

Zebrafish embryos exposed to high glucose for 24 hrs are transiently hyperglycemic while normoglycemia is restored after glucose exposure. Larvae and adults with embryonic glucose exposure are normoglycemic. Embryos showed an upregulation of hexokinase and pyruvate Kinase expression when assessed at 120 hpf, but no change in expression was detected in larvae. Embryos exposed to glucose showed increased lipid accumulation by ORO staining (0.22 ±0.01 Vs 0.17±0.01) while larvae showed a 5‐fold increase in adiposity. Adult fish develop obesity characterized by increased BMI (0.83±26.34 Vs. 0.60± 33.89) kg/m2 and fat mass (12.07± 2.92 Vs 3.4± 0.4) g. Embryos showed increase in both acca mRNA expression (3‐folds) and activation (decreased phosphorylation). Interestingly, acca expression remained increased in larvae while glycemia was normal. Moreover, there was a significant increase in cholesterol (57.92± 0.7 Vs 34.8±1.01 µM) and triglyceride levels in glucose exposed embryos compared to controls (4.1± 0.75 Vs 0.98±0.27 µM). Our data in embryos revealed an increase in mitochondria number validated by an increase in the expression of PGC‐1α/β. Finally, ORO staining showed that embryonic lipid accumulation was decreased to normal levels, by metformin or ND646 exposure when co‐administered with glucose.

Conclusion and significance:

Together our results show that embryonic glucose exposure alters developmental programming, including lipid homeostasis dysregulation that is persistent in larvae and adult. However, it can be rescued by pharmacological approaches.

100 项与 ND-654 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肝细胞癌	临床前	美国	The General Hospital Corp.	2016-07-15
肝细胞癌	临床前	美国	Nimbus Therapeutics LLC	2016-07-15
肝细胞癌	临床前	美国	Schrödinger, Inc.	2016-07-15
肿瘤	药物发现	美国	Gilead Apollo LLC	-